WallStSmart
ACLX

Arcellx Inc

NASDAQ: ACLX · HEALTHCARE · BIOTECHNOLOGY

$115.07
+0.00% today

Updated 2026-04-28

Market cap
$6.73B
P/E ratio
P/S ratio
302.04x
EPS (TTM)
$-4.07
Dividend yield
52W range
$48 – $115
Volume
2.8M

Arcellx Inc (ACLX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-6.86M$-18.77M$-28.66M$-54.24M$-99.30M$207.57M$-83.47M$-210.26M
Capital expenditures$479000.00$3.83M$888000.00$5.78M$2.28M$21.43M$13.43M$2.33M
Depreciation
Stock-based comp$66000.00$136000.00$1.05M$6.75M$21.54M$41.79M$61.09M$77.89M
Free cash flow$-7.34M$-22.60M$-29.55M$-60.02M$-101.58M$186.15M$-96.90M$-212.59M
Investing cash flow
Financing cash flow
Dividends paid$119.12M$271.40M
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Arcellx Inc's revenue?

Arcellx Inc's trailing twelve-month revenue is $22.29M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ACLX?

In its most recent fiscal year, ACLX ran a gross margin of 70.03%, an operating margin of -1,135.61%, and a net margin of -1,027.25%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ACLX generate?

ACLX produced $-212.59M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.